Skip to content
OpenCapital
Get started

Aurinia Pharmaceuticals AUPH Finance Lease, Right-of-Use Asset, after Accumulated Amortization

Finance Lease, Right-of-Use Asset, after Accumulated Amortization at other companies

Incyte logo
IncyteINCY
——

Segments

By geography

See full
Visp, Switzerland$69.5M-20.0%

Other financials

Income statement

See full
Revenue$77.7M+24.4%
Gross profit$71.2M+32.1%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Cash & equivalents$41.0M-38.3%
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation

See full
Market cap$2.39B+78.5%

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseRightOfUseAsset.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's finance lease, right-of-use asset, after accumulated amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aurinia Pharmaceuticals's finance lease, right-of-use asset, after accumulated amortization?
Aurinia Pharmaceuticals (AUPH) reported finance lease, right-of-use asset, after accumulated amortization of $69.51M in Q1 2026.
How has Aurinia Pharmaceuticals's finance lease, right-of-use asset, after accumulated amortization changed year-over-year?
Aurinia Pharmaceuticals's finance lease, right-of-use asset, after accumulated amortization decreased by 20.6% year-over-year, from $87.58M to $69.51M.